AGTR2 and kidney disorder: A number of AT2 receptor agonists have emerged from animal studies including Compound 21 (Kaschina et al., 2008), MOR107 (Wagenaar et al., 2013) and NP-6A4 (Gavini et al., 2021); however, to date, therapeutic effects of these compounds in ameliorating CV and renal diseases have yet to be thoroughly tested in phase II/III human trials.